Author/Authors :
Sulaiman، نويسنده , , Ghassan M. and Ad’hiah، نويسنده , , Ali H. and Al-Sammarrae، نويسنده , , Khulood W. and Bagnati، نويسنده , , Renzo and Frapolli، نويسنده , , Roberta and Bello، نويسنده , , Ezia and Uboldi، نويسنده , , Sarah and Romano، نويسنده , , Michela and Panini، نويسنده , , Nicol? and Scanziani، نويسنده , , Eugenio and Pezzolato، نويسنده , , Marzia and Erba، نويسنده , , Eugenio and D’In، نويسنده ,
Abstract :
The study was designed to evaluate anti-tumour properties of Iraqi propolis collected from Mosul region (M) on HL-60 and HCT-116 cell lines and on HCT-116 in vivo. M induced an inhibitory effect against the proliferation of HL-60 and colony potential of HCT-116 cells. The apoptosis in HL-60 cells was associated with down-regulation of Bcl-2 and activation of Bax, while in HCT-116 cells, necrotic features were observed; size of cells was dramatically increased by swelling of cytoplasm and loss of membrane integrity, cell rupture and release of cellular contents. Analysis of BrdU/DNA cell cycle in both cell lines showed that M induced cell cycle perturbations in both BrdU positive and BrdU negative cells. The exposure of HL-60 to M caused γ-H2AX in a dose dependent manner and was associated with induction of apoptosis. The experiments in HCT-116 tumor-bearing mice showed that oral administration of propolis at doses that caused no detectable toxicity was associated with a decrease in mitotic cells and an increase in endoreduplications, increased p53 and decreased Ki-67 expression of cells in tumor sections. This study provides the rationale to investigate the potential beneficial effect of propolis in the diet of patients receiving anti-cancer therapies.
